Clinical Trial Update: Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally [Phase 3]

View source ↗

Summary

A global Phase 3 trial of lumateperone as monotherapy for bipolar depression has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• Lumateperone (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Bipolar Depression | Phase 3 | Status: COMPLETED | Results posted: 2022-06-03